Renal Insufficiency
Conditions
Keywords
Kidney Transplantation, Atorvastatin, C-Reactive Protein, Biopsy, Interleukin
Brief summary
Renal Insufficiency is a priority disease in health system, which may require renal replacement therapy based on renal transplantation, which is considered as therapy of choice. During the procedure of renal transplantation, the graft could be damaged by ischemia-reperfusion which generates complications in its function. Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in renal transplantation.
Detailed description
Objective: Evaluate anti-inflammatory effect of atorvastatin on renal graft in living donor transplantation. Material and methods: Controlled, double-blind clinical trial with posterior following for 12 months. Composed by 48 patients, randomized manner, realized at the Transplant Department of Western Medical Center, Mexican Institute of Social Security. Universe was patients accepted as kidney donors. Patients were randomized in two groups (study or control) the intervention was implemented 4 weeks before kidney transplant. Previous surgical procedure, in a blood sample, C-Reactive Protein (C-RP) and laboratory control were measured. During surgical procedure, a biopsy was obtained to measure IL-6 and tumoral necrosis factor alpha by immunohistochemistry. 24 hours after surgical procedure, 3 and 12 months of following, kidney function, complications and graft survival were registered. During surgical procedure, 3 months and 12 months of following, biopsies were obtain to performed histopathological analysis of scale of Banff The statistical analysis was performed according to the nature of variables, for continuous data using measures of central tendency and dispersion and for the qualitative data with frequencies and percentages.
Interventions
DRUGAtorvastatin
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
DRUGPlacebo
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
Sponsors
Instituto Mexicano del Seguro Social
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Accepted as kidney donor * Voluntary participation * Informed consent accepted * 85% fulfillment of atorvastatin treatment
Exclusion criteria
* Hypersensibility to Atorvastatin * Smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C-Reactive Protein evolution in donors | Basal and 4 weeks later | C-Reactive Protein was measured when patients (donors) were accepted in the study and 4 weeks later. The last blood sample was taken the day of surgical procedure. |
| Kidney graft rejection using scale of BANFF | Basal, 3 months and 12 months | During surgical procedure and before organ transplantation, basal biopsy was obtain. In the following at 3 and 12 months after kidney transplantation, were performed the other two biopsy. Alterations between groups were registered. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kidney function evolution after transplant | 24 hours, 3 months and 12 months | In blood samples, after kidney transplantation, creatinine and urea were measured. Differences in evolution and alteration between the 2 groups were registered |
| Interleukin and tumor necrosis factor alpha. | Basal | During surgical procedure and before organ transplantation, the biopsy was obtain to measure interleukin 6 and tumor necrosis factor alpha, observing alteration between groups. |
| Complications | 24 hours, 3 months and 12 months | During surgical procedure, any kind of complication was registered, the same right after surgery and in the following. |
Countries
Mexico
Outcome results
None listed